Close

Gilead Sciences (GILD) Announces Completion of Acquisition of CymaBay (CBAY) Mar 22, 2024 09:18AM
Gilead Sciences Announces Completion of Acquisition of CymaBay Mar 22, 2024 09:18AM
Gilead Sciences (GILD) Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay (CBAY) Tender Offer Mar 11, 2024 08:24AM
CymaBay Therapeutics (CBAY) Announces EMA Acceptance of Marketing Authorization Application for Seladelpar Mar 4, 2024 08:04AM
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis Mar 4, 2024 08:00AM
View Older Stories

Feb 28, 2024 04:45PM CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
Feb 21, 2024 10:36PM CymaBay Therapeutics (CBAY) Announces Publication of Positive Phase 3 RESPONSE Data of Seladelpar
Feb 21, 2024 05:43PM The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
Feb 20, 2024 04:05PM CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 12, 2024 08:45AM CymaBay Therapeutics (CBAY) Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
Feb 12, 2024 08:45AM CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis
Feb 12, 2024 08:32AM Gilead Sciences (GILD) to Acquire CymaBay Therapeutics (CBAY) for $32.50 Per Share, $4.3 Billion
Feb 12, 2024 08:30AM Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Jan 31, 2024 08:00AM CymaBay Therapeutics to Participate in Upcoming Investment Conferences
Jan 16, 2024 04:28PM CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 3, 2024 08:04AM CymaBay (CBAY) Says New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in PBC in Phase 3 Post-Hoc Analysis of Seladelpar
Jan 3, 2024 08:00AM New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary Biliary Cholangitis in Phase 3 Post-Hoc Analysis of CymaBay's Seladelpar
Jan 2, 2024 08:00AM CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
Dec 18, 2023 04:05PM CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 15, 2023 08:00AM CymaBay Therapeutics (CBAY) Submits NDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
Dec 15, 2023 08:00AM CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
Nov 17, 2023 04:15PM CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 13, 2023 08:00AM CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®
Nov 7, 2023 04:04PM CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update
Nov 6, 2023 08:00AM CymaBay Therapeutics to Present at Upcoming Investment Conferences
Nov 1, 2023 08:00AM CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis
Oct 31, 2023 04:05PM CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023
Oct 23, 2023 04:05PM CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023
Oct 23, 2023 08:09AM CymaBay Therapeutics (CBAY) Announces Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or W
Oct 23, 2023 08:00AM Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis
Oct 18, 2023 08:00AM CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Oct 16, 2023 04:05PM CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 21, 2023 08:02AM CymaBay Therapeutics (CBAY) Initiates AFFIRM Phase 3b/4 Study of the Effect of Seladelpar
Sep 21, 2023 08:00AM CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
Sep 15, 2023 08:00AM CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference
Sep 7, 2023 07:02AM CymaBay's (CBAY) Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis
Sep 7, 2023 07:00AM CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis
Sep 6, 2023 04:05PM CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023
Aug 28, 2023 04:29PM CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 10, 2023 04:04PM CymaBay Reports Second Quarter and Six Months Ended June 30, 2023 Financial Results and Provides Corporate Update
Aug 10, 2023 08:00AM CymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase
Aug 3, 2023 04:05PM CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023
Jun 21, 2023 06:00AM CymaBay Therapeutics (CBAY) Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels
Jun 21, 2023 03:00AM CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels
Jun 7, 2023 02:00AM CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023
May 15, 2023 04:04PM CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 08:00AM CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023
May 9, 2023 08:00AM CymaBay Names Harish Shantharam Chief Financial Officer
Apr 21, 2023 08:02AM CymaBay Therapeutics (CBAY) Announces Publication of Results From the ENHANCE Study of Seladelpar
Apr 21, 2023 08:00AM CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
Apr 17, 2023 08:00AM CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Mar 16, 2023 04:04PM CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update
Mar 9, 2023 04:05PM CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
Mar 1, 2023 08:00AM CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
Feb 6, 2023 08:00AM CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference
View Older Stories